UNITED THERAPEUTICS CORP (UTHR) Stock News
NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD
UTHR Latest News, Press Relases and Analysis
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors.
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a strong portfolio led by Tyvaso, its inhaled therapy for pulmonary hypertension, and a growing pipeline targeting pulmonary arterial hypertension (PAH). Its existing therapies are leading to stronger topline and earnings growth; the 17% year-over-year growth […]
Mentions: UBS
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Mentions: MCK
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment’s impending Phase 2 data for pulmonary arterial hypertension. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of […]
Why Summit Therapeutics Stock Tanked Today
An analyst launched coverage of the biotech stock. An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. Well before market open that day, Leerink Partners' Daina Graybosch initiated coverage on Summit stock.
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Prediction: This Tariff-Resistant Growth Stock Could Join the Trillion-Dollar Club by 2030
Netflix stock has been on a roll in 2025, as the company's streaming business is insulated from tariffs.
Is This New Crypto Stock a Potential Millionaire-Maker?
On its first day of trading on the NYSE, Circle Internet Group soared 168%. Circle is the second-largest stablecoin issuer in the world. Based on future growth projections for the stablecoin industry, Circle could be ready to skyrocket in value.
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: CPRX
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: CORT
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies. Even after his passing in 2024, billionaire investor and […]